St. Jude Medical (NYSE:STJ) said its launched the Ilumien Optis device in Japan, calling it the only medical device on the market to combine fractional flow reserve and optical coherence tomography technology to allow doctors to evaluate the state and severity of coronary lesions.
The St. Paul, Minn.-based medical device company said the Ilumien Optis combines its PressureWire Aeris wireless FFR technology with its Dragonfly JP imaging catheter. The FFR tech measures the flow of blood across lesions in the arteries that feed the heart muscle, so that cardiologists can determine whether a stent is needed.
The OCT tech uses near-infrared light to provide images of the lesions, according to a press release.
"We are very pleased to offer the Ilumien Optis system in Japan, which is a world leader in imaging technology utilization," St. Jude Medical Japan president William Phillips said in prepared remarks. "The new system is the latest in [percutaneous coronary intervention" optimization technology, and helps physicians understand the needs of each patient, ultimately resulting in better medical decision making and overall cost-effective treatment."